Lillie James Woodruff 4

4 · MapLight Therapeutics, Inc. · Filed Apr 17, 2026

AI-generated summary of this filing

Updated Apr 17, 2026

MapLight (MPLT) CSO Lillie James Woodruff Sells 4,513 Shares

What Happened

Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics (MPLT), sold a total of 4,513 shares in open-market/private sales on April 15–16, 2026 for aggregate proceeds of approximately $122,575. Breakdown: 1,730 shares @ $26.82 (Apr 15) = $46,399; 686 shares @ $27.01 (Apr 16) = $18,529; 2,097 shares @ $27.49 (Apr 16) = $57,647. These transactions are reported as sales (S) and per the filing some shares were sold to cover statutory tax withholding related to RSU vesting.

Key Details

Transaction dates and prices:
- 2026-04-15: 1,730 shares @ $26.82 = $46,399
- 2026-04-16: 686 shares @ $27.01 = $18,529
- 2026-04-16: 2,097 shares @ $27.49 = $57,647
Total sold: 4,513 shares for ~$122,575.
Footnotes: filing notes that some shares were sold to cover tax withholding on vested RSUs (F1). Reported prices are weighted averages with sales occurring across price ranges (see footnotes F2, F4, F5). The filing also notes 808 shares were acquired under the company’s employee stock purchase plan on March 31, 2026 (F3).
Shares owned after the transactions: not specified in the provided excerpt.
Filing timeliness: Report is dated Apr 17, 2026 for transactions through Apr 15–16, 2026 — the filing appears to have been made promptly.

Context

These were outright sales (S) rather than purchases or option exercises. Sales to cover tax withholding for RSU vesting are common and typically routine (not necessarily a directional signal about insider view). No options exercised or gifts were reported in the provided transactions.

Form 4

Period: 2026-04-15

Chief Scientific Officer

Transactions

Sale
Voting Common Stock
[F1][F2][F3]
2026-04-15$26.82/sh−1,730$46,399→ 297,940 total
Sale
Voting Common Stock
[F1][F4]
2026-04-16$27.01/sh−686$18,529→ 297,254 total
Sale
Voting Common Stock
[F1][F5]
2026-04-16$27.49/sh−2,097$57,647→ 295,157 total

Footnotes (5)

[F1]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units.
[F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.33 to $27.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5).
[F3]Includes 808 shares acquired under the Issuer's stock purchase plan on March 31, 2026.
[F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2201 to $27.2197 inclusive.
[F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $27.9898 inclusive.

Signature

/s/ Kristopher L. Hanson, Attorney-in-Fact|2026-04-17

1 file